Abstract

Hepatitis A virus (HAV) and hepatitis E virus (HEV) are causative agents of acute viral hepatitis transmitted via the fecal–oral route. Both viruses place a heavy burden on the public health and economy of developing countries. To test the possibility that HAV could be used as an expression vector for the development of a combination vaccine against hepatitis A and E infections, recombinant HAV-HEp148 was created as a vector to express an HEV neutralization epitope (HEp148) located at aa 459–606 of the HEV capsid protein. The recombinant virus expressed the HEp148 protein in a partially dimerized state in HAV-susceptible cells. Immunization with the HAV-HEp148 virus induced a strong HAV- and HEV-specific immune response in mice. Thus, the present study demonstrates a novel approach to the development of a combined hepatitis A and E vaccine.

Highlights

  • Hepatitis A virus (HAV) and hepatitis E virus (HEV) are causative agents of acute viral hepatitis.HAV is a small, non-enveloped virus with a positive-sense RNA in the family Picornaviridae [1].HAV infection is responsible for approximately 1.4 million new cases worldwide each year

  • HAV titers were determined by inoculating the confluent monolayer of cells cultured in 25 cm3 culture flasks, and infection was verified by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA)

  • The sequencing results showed that the 444 nts sequence was inserted into the polylinker at the 2A/2B junction of pT7-HAV, as expected, and that the reading frame was correct

Read more

Summary

A Recombinant HAV Expressing a Neutralization

Xiang Kui 1,2 , Kusov Yuri 3,4 , Ying Guan 5 , Yan Wang 2 , Shan Yi 1 , Jinyuan Wu 1 , Na Yin 1 , Yan Zhou 1 , Hongjun Li 1, * and Maosheng Sun 1, *. German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems Site, University of Lübeck, 23562 Lübeck, Germany. Received: 22 July 2017; Accepted: 9 September 2017; Published: 15 September 2017

Introduction
Cell Cultures
Plasmids and Constructs
Schematic
RNA Transcription and Transfection
RT-PCR and Sequence Analysis of Viral RNA
Immunofluorescence for HAV and HEV Capsid Protein
Non-Denaturing Gel Electrophoresis and Western Blotting
Recombinant HAV Amplification and Titer Determination
2.10. Immunogenicity Analysis of the Recombinant Virus and Serum Collection
2.11. Anti-HAV and HEV Antibody Detection
Results
Rescue
Immunofluorescence
As shown in the4data
Profiles of HAVand HEV-specific
Discussion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.